Dasatinib and navitoclax act synergistically to target NUP98-NSD1 + / FLT3 -ITD + acute myeloid leukemia

Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3 -ITD is associated with unfavorable prognosis and represents a particularly challenging treatment group. To identify novel effective therapies for this AML subtype, we screened patient cells and engineered cell models with over 300 compounds. We found that mouse hematopoietic progenitors co-expressing NUP98-NSD1 and FLT3 -ITD had significantly increased sensitivity to FLT3 and MEK-inhibitors compared to cells expressing either aberration alone ( P < 0.001). The cells expressing NUP98-NSD1 alone had significantly increased sensitivity to BCL2-inhibitors ( P = 0.029). Furthermore, NUP98-NSD1 + /FLT3- ITD + patient cells were also very sensitive to BCL2-inhibitor navitoclax, although the highest select sensitivity was found to SRC/ABL-inhibitor dasatinib (mean IC 50 = 2.2 nM). Topoisomerase inhibitor mitoxantrone was the least effective drug against NUP98-NSD1 + /FLT3- ITD + AML cells. Of the 25 significant hits, four remained significant also compared to NUP98-NSD1 - /FLT3- ITD + AML patients. We found that SRC/ABL-inhibitor dasatinib is highly synergistic with BCL2-inhibitor navitoclax in NUP98-NSD1 + /FLT3- ITD + cells. Gene expression analysis supported the potential relevance of dasatinib and navitoclax by revealing significantly higher expression of BCL2A1 , FGR , and LCK in NUP98-NSD1 + /FLT3- ITD + patients compared to healthy CD34+ cells. Our data suggest that dasatinib–navitoclax combination may offer a clinically relevant treatment strategy for AML with NUP98-NSD1 and concomitant FLT3- ITD.